| Patient | John Henry Holliday |
|---|---|
| Date of birth | 2004-08-14 |
| Identifiers | MRN HR-NI007-SYN; SSN (made up) 000-07-8153 |
| Document date | 2026-11-01 |
| Author | Martin Beaumont, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Diagnosis of cavitary pulmonary tuberculosis: sputum, chest X-ray, baseline tests, public-health report, home isolation, and alcohol assessment with a safety assessment. Concerns: He wants to get back to his dental practice as soon as it is safe for his patients; He is frightened by the diagnosis and wants to know that it can be cured. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Isoniazid 300 mg tablet, one tablet daily | 300 mg once daily by video-observed therapy with the health department, seven days a week, for six months | Oral route | 2026-02-12 to 2026-08-13 | completed | S |
| Rifampin 300 mg capsules, two capsules (600 mg) daily | 600 mg once daily on an empty stomach by video-observed therapy with the health department, seven days a week, for six months | Oral route | 2026-02-12 to 2026-08-13 | completed | S |
| Pyrazinamide 500 mg tablets, three tablets (1500 mg) daily | 1500 mg once daily by video-observed therapy with the health department, seven days a week, for the eight-week intensive phase | Oral route | 2026-02-12 to 2026-04-08 | completed | S |
| Ethambutol 400 mg tablets, three tablets (1200 mg) daily | 1200 mg once daily by video-observed therapy with the health department, seven days a week, until susceptibility results return | Oral route | 2026-02-12 to 2026-03-10 | stopped | S |
| Vitamin B6 (pyridoxine) 50 mg tablet, one tablet daily | 50 mg once daily with isoniazid | Oral route | 2026-02-12 to 2026-08-13 | completed | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| Chest X-ray, two views: right upper lobe consolidation with a 3 cm thick-walled cavity; no effusion or hilar enlargement | 2026-02-10 to 2026-02-10 | completed | S |
| Chest X-ray, two views, at the end of treatment: cavity closed, with residual right upper lobe scarring; kept as the baseline for any future comparison | 2026-08-18 to 2026-08-18 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 2022-08-30 | Tetanus, diphtheria, and pertussis (Tdap) booster | completed | S |
| 2026-09-22 | Influenza vaccine, 2026-2027 season | completed | S |
| 2026-09-22 | Hepatitis B vaccine (HepB-CpG), dose 1 of 2 | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| 1872 | Developed a bad cough shortly after beginning to practice dentistry | D (CLM-0004) |
| Relative | Condition | Age at death | Evidence |
|---|---|---|---|
| mother | Pulmonary tuberculosis; died of it in 1866 | D (CLM-0002) |
| Concern | Status | Evidence |
|---|---|---|
| He wants to get back to his dental practice as soon as it is safe for his patients | active | S |
| He is frightened by the diagnosis and wants to know that it can be cured | active | S |
Most recent measures: Hemoglobin [Mass/volume] in Blood 14.4 on 2026-08-18; Leukocytes [#/volume] in Blood by Automated count 9.4 on 2026-02-10; Platelets [#/volume] in Blood by Automated count 412 on 2026-02-10; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 64 on 2026-05-19; Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 58 on 2026-05-19; Bilirubin.total [Mass/volume] in Serum or Plasma 0.9 on 2026-05-19; Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 98 on 2026-05-19; Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma 78 on 2026-02-10; Albumin [Mass/volume] in Serum or Plasma 3.4 on 2026-02-10; Creatinine [Mass/volume] in Serum or Plasma 0.86 on 2026-02-10; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 124 on 2026-02-10; Glucose [Mass/volume] in Serum or Plasma 90 on 2026-02-10; Hemoglobin A1c/Hemoglobin.total in Blood 5.2 on 2026-02-10; Visual acuity uncorrected Right eye by ETDRS eye chart 85 on 2026-02-24; Visual acuity uncorrected Left eye by ETDRS eye chart 84 on 2026-02-24; Total score [AUDIT] 15 on 2026-02-10; Total score [AUDIT-C] 3 on 2026-09-22; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 3 on 2026-08-18; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 on 2026-09-22 [S]
Strengths and supports: engagement in care [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Pulmonary tuberculosis, right upper lobe cavitary, sputum smear-positive, confirmed by nucleic acid amplification without rifampin resistance | active | confirmed | A15.0 | S — Synthetic modern coding of his documented pulmonary tuberculosis at the time of diagnosis; the bacteriology is synthetic. |
| Alcohol use disorder, mild, with binge drinking | active | confirmed | F10.10 | S — Synthetic modern coding anchored to the documented heavy drinking; the severity and the criteria met are synthetic. |
| Acute viral gastroenteritis during tuberculosis treatment, with a mild aminotransferase rise below the threshold for drug-induced liver injury; resolved | resolved | confirmed | A08.4 | S — Synthetic intercurrent illness chosen to teach the assessment of nausea on isoniazid and rifampin; it does not echo a documented illness. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-02-10 | Hemoglobin [Mass/volume] in Blood | 12.6 | g/dL | 13.2-16.6 g/dL | Low | S |
| 2026-02-10 | Leukocytes [#/volume] in Blood by Automated count | 9.4 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-02-10 | Platelets [#/volume] in Blood by Automated count | 412 | 10*3/uL | 150-400 10*3/uL | High | S |
| 2026-02-10 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 34 | U/L | 7-56 U/L | Normal | S |
| 2026-02-10 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 38 | U/L | 10-40 U/L | Normal | S |
| 2026-02-10 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.6 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 2026-02-10 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 92 | U/L | 40-129 U/L | Normal | S |
| 2026-02-10 | Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma | 78 | U/L | 8-61 U/L | High | S |
| 2026-02-10 | Albumin [Mass/volume] in Serum or Plasma | 3.4 | g/dL | 3.5-5 g/dL | Low | S |
| 2026-02-10 | Creatinine [Mass/volume] in Serum or Plasma | 0.86 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-02-10 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 124 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-02-10 | Glucose [Mass/volume] in Serum or Plasma | 90 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-02-10 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.2 | % | <=5.6% | Normal | S |
| 2026-02-10 | Visual acuity uncorrected Right eye by ETDRS eye chart | 85 | {letters} | >=80 | Normal | S |
| 2026-02-10 | Visual acuity uncorrected Left eye by ETDRS eye chart | 85 | {letters} | >=80 | Normal | S |
| 2026-02-10 | Total score [AUDIT] | 15 | {score} | S | ||
| 2026-02-10 | Total score [AUDIT-C] | 9 | {score} | S | ||
| 2026-02-10 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 6 | {score} | S | ||
| 2026-02-24 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 41 | U/L | 7-56 U/L | Normal | S |
| 2026-02-24 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 39 | U/L | 10-40 U/L | Normal | S |
| 2026-02-24 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.7 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 2026-02-24 | Visual acuity uncorrected Right eye by ETDRS eye chart | 85 | {letters} | >=80 | Normal | S |
| 2026-02-24 | Visual acuity uncorrected Left eye by ETDRS eye chart | 84 | {letters} | >=80 | Normal | S |
| 2026-02-24 | Total score [AUDIT-C] | 4 | {score} | S | ||
| 2026-03-17 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 52 | U/L | 7-56 U/L | Normal | S |
| 2026-03-17 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 47 | U/L | 10-40 U/L | High | S |
| 2026-03-17 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.8 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 2026-03-17 | Total score [AUDIT-C] | 2 | {score} | S | ||
| 2026-04-14 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 38 | U/L | 7-56 U/L | Normal | S |
| 2026-04-14 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 35 | U/L | 10-40 U/L | Normal | S |
| 2026-04-14 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.7 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 2026-04-14 | Total score [AUDIT-C] | 1 | {score} | S | ||
| 2026-08-18 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 30 | U/L | 7-56 U/L | Normal | S |
| 2026-08-18 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 28 | U/L | 10-40 U/L | Normal | S |
| 2026-08-18 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.6 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 2026-08-18 | Hemoglobin [Mass/volume] in Blood | 14.4 | g/dL | 13.2-16.6 g/dL | Normal | S |
| 2026-08-18 | Total score [AUDIT-C] | 3 | {score} | S | ||
| 2026-08-18 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | {score} | S | ||
| 2026-05-19 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 64 | U/L | 7-56 U/L | High | S |
| 2026-05-19 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 58 | U/L | 10-40 U/L | High | S |
| 2026-05-19 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.9 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 2026-05-19 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 98 | U/L | 40-129 U/L | Normal | S |
| 2026-05-19 | Total score [AUDIT-C] | 4 | {score} | S | ||
| 2026-09-22 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S | ||
| 2026-09-22 | Total score [AUDIT-C] | 3 | {score} | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-02-10 | Body height | 178 | cm | S |
| 2026-02-10 | Body weight | 58 | kg | S |
| 2026-02-10 | Body mass index (BMI) [Ratio] | 18.3 | kg/m2 | S |
| 2026-02-10 | Systolic blood pressure | 112 | mm[Hg] | S |
| 2026-02-10 | Diastolic blood pressure | 70 | mm[Hg] | S |
| 2026-02-10 | Heart rate | 104 | /min | S |
| 2026-02-10 | Respiratory rate | 20 | /min | S |
| 2026-02-10 | Body temperature | 37.8 | Cel | S |
| 2026-02-10 | Oxygen saturation in Arterial blood by Pulse oximetry | 95 | % | S |
| 2026-02-24 | Body height | 178 | cm | S |
| 2026-02-24 | Body weight | 59 | kg | S |
| 2026-02-24 | Body mass index (BMI) [Ratio] | 18.6 | kg/m2 | S |
| 2026-02-24 | Systolic blood pressure | 114 | mm[Hg] | S |
| 2026-02-24 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 2026-02-24 | Heart rate | 92 | /min | S |
| 2026-02-24 | Respiratory rate | 18 | /min | S |
| 2026-02-24 | Body temperature | 37.3 | Cel | S |
| 2026-02-24 | Oxygen saturation in Arterial blood by Pulse oximetry | 96 | % | S |
| 2026-03-17 | Body height | 178 | cm | S |
| 2026-03-17 | Body weight | 61 | kg | S |
| 2026-03-17 | Body mass index (BMI) [Ratio] | 19.3 | kg/m2 | S |
| 2026-03-17 | Systolic blood pressure | 116 | mm[Hg] | S |
| 2026-03-17 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 2026-03-17 | Heart rate | 84 | /min | S |
| 2026-03-17 | Respiratory rate | 16 | /min | S |
| 2026-03-17 | Body temperature | 36.8 | Cel | S |
| 2026-03-17 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 2026-04-14 | Body height | 178 | cm | S |
| 2026-04-14 | Body weight | 62.5 | kg | S |
| 2026-04-14 | Body mass index (BMI) [Ratio] | 19.7 | kg/m2 | S |
| 2026-04-14 | Systolic blood pressure | 116 | mm[Hg] | S |
| 2026-04-14 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 2026-04-14 | Heart rate | 78 | /min | S |
| 2026-04-14 | Respiratory rate | 16 | /min | S |
| 2026-04-14 | Body temperature | 36.7 | Cel | S |
| 2026-04-14 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-08-18 | Body height | 178 | cm | S |
| 2026-08-18 | Body weight | 65.5 | kg | S |
| 2026-08-18 | Body mass index (BMI) [Ratio] | 20.7 | kg/m2 | S |
| 2026-08-18 | Systolic blood pressure | 118 | mm[Hg] | S |
| 2026-08-18 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 2026-08-18 | Heart rate | 72 | /min | S |
| 2026-08-18 | Respiratory rate | 14 | /min | S |
| 2026-08-18 | Body temperature | 36.6 | Cel | S |
| 2026-08-18 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-05-19 | Body height | 178 | cm | S |
| 2026-05-19 | Body weight | 61.8 | kg | S |
| 2026-05-19 | Body mass index (BMI) [Ratio] | 19.5 | kg/m2 | S |
| 2026-05-19 | Systolic blood pressure | 108 | mm[Hg] | S |
| 2026-05-19 | Diastolic blood pressure | 68 | mm[Hg] | S |
| 2026-05-19 | Heart rate | 98 | /min | S |
| 2026-05-19 | Respiratory rate | 16 | /min | S |
| 2026-05-19 | Body temperature | 37.4 | Cel | S |
| 2026-05-19 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-09-22 | Body height | 178 | cm | S |
| 2026-09-22 | Body weight | 66 | kg | S |
| 2026-09-22 | Body mass index (BMI) [Ratio] | 20.8 | kg/m2 | S |
| 2026-09-22 | Systolic blood pressure | 118 | mm[Hg] | S |
| 2026-09-22 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 2026-09-22 | Heart rate | 68 | /min | S |
| 2026-09-22 | Respiratory rate | 14 | /min | S |
| 2026-09-22 | Body temperature | 36.6 | Cel | S |
| 2026-09-22 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 2026-02-10 | Diagnosis of cavitary pulmonary tuberculosis: sputum, chest X-ray, baseline tests, public-health report, home isolation, and alcohol assessment with a safety assessment | finished | S |
| 2026-02-24 | Two-week follow-up on treatment with infectious diseases consultation | finished | S |
| 2026-03-17 | Five-week review: susceptibility results, release from isolation, and liver monitoring | finished | S |
| 2026-04-14 | End of the intensive phase: two-month sputum and the start of the continuation phase | finished | S |
| 2026-08-18 | End-of-treatment review after six months | finished | S |
| 2026-05-19 | Same-day sick visit for nausea and vomiting during tuberculosis treatment | finished | S |
| 2026-09-22 | Adult preventive visit | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Infectious diseases consultation to confirm the regimen and plan monitoring for cavitary pulmonary tuberculosis in a man who drinks heavily | completed | GL-ATS-TB-2016, GL-ATS-TB-2025 | S |
| Standard treatment: isoniazid, rifampin, pyrazinamide, and ethambutol for eight weeks, then isoniazid and rifampin for eighteen weeks, by video-observed therapy with the health department, with pyridoxine | completed | GL-ATS-TB-2016 | S |
| Monitoring: monthly symptom and weight check, sputum smear and culture monthly until two consecutive cultures are negative, liver tests at two weeks and monthly because of alcohol, and vision checks while on ethambutol | completed | GL-ATS-TB-2016, GL-ATS-HEPATOTOX-2006 | S |
| Public health: same-day report to the local health department, home isolation until noninfectious, and a contact investigation of his household, coworkers, and patients led by the health department | completed | GL-CDC-CONTACT-2005, GL-ATS-TB-2016 | S |
| Alcohol care: brief intervention at diagnosis, a goal of no alcohol during treatment, counseling with a substance-use counselor, medication offered, AUDIT-C at each visit, and a safety review with the 988 Suicide & Crisis Lifeline at every visit | completed | GL-USPSTF-ALC-2018, GL-SUD-2021, GL-SUICIDE-2024 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| Complete 182 doses of treatment under video-observed therapy within six months | 2026-08-18 | completed | All 182 doses completed: 56 in the intensive phase and 126 in the continuation phase, with one dose held during a stomach illness and made up at the end | S |
| Sputum culture negative at two months | 2026-08-18 | completed | Two-month culture showed no growth, so the continuation phase stayed at four months | S |
| No alcohol during treatment, to protect his liver | 2026-08-18 | active | Not fully met: no drinking for most of the six months, with one evening of heavy drinking at a party about three months into treatment; AUDIT-C 3 at the end | S |
| Return to work once he is no longer infectious | 2026-03-17 | completed | Released from home isolation after three negative sputum smears and back at work four weeks into treatment | S |
| Weight back to at least 64 kg by the end of treatment | 2026-08-18 | completed | 65.5 kg at the end of treatment, from 58.0 kg at diagnosis | S |
Structured synthetic safety assessment on 2026-02-10: current ideation absent, intent absent, plan absent. Routine outpatient care. A new serious diagnosis, isolation, and heavy drinking can raise suicide risk, so safety is reviewed at every visit. He saved the 988 Suicide & Crisis Lifeline in his phone. No firearm in the home [S]